Your browser doesn't support javascript.
loading
Mechanisms of Tumor Growth Inhibition by Depletion of γ-Glutamylcyclotransferase (GGCT): A Novel Molecular Target for Anticancer Therapy.
Kageyama, Susumu; Ii, Hiromi; Taniguchi, Keiko; Kubota, Shigehisa; Yoshida, Tetsuya; Isono, Takahiro; Chano, Tokuhiro; Yoshiya, Taku; Ito, Kosei; Yoshiki, Tatsuhiro; Kawauchi, Akihiro; Nakata, Susumu.
Affiliation
  • Kageyama S; Department of Urology, Shiga University of Medical Science, Shiga 520-2192, Japan. kageyama@belle.shiga-med.ac.jp.
  • Ii H; Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan. iihiromi@mb.kyoto-phu.ac.jp.
  • Taniguchi K; Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan. kd16006@poppy.kyoto-phu.ac.jp.
  • Kubota S; Department of Urology, Shiga University of Medical Science, Shiga 520-2192, Japan. kubota@belle.shiga-med.ac.jp.
  • Yoshida T; Department of Urology, Shiga University of Medical Science, Shiga 520-2192, Japan. yoshida9@belle.shiga-med.ac.jp.
  • Isono T; Central Research Laboratory, Shiga University of Medical Science, Shiga 520-2192, Japan. isono@belle.shiga-med.ac.jp.
  • Chano T; Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga 520-2192, Japan. chano@belle.shiga-med.ac.jp.
  • Yoshiya T; Peptide Institute Inc., Osaka 567-0085, Japan. t.yoshiya@peptide.co.jp.
  • Ito K; Department of Molecular Bone Biology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8588, Japan. itok@nagasaki-u.ac.jp.
  • Yoshiki T; Department of Urology, Shiga University of Medical Science, Shiga 520-2192, Japan. yoshiki@mb.kyoto-phu.ac.jp.
  • Kawauchi A; Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan. yoshiki@mb.kyoto-phu.ac.jp.
  • Nakata S; Department of Urology, Shiga University of Medical Science, Shiga 520-2192, Japan. kawauchi@belle.shiga-med.ac.jp.
Int J Mol Sci ; 19(7)2018 Jul 14.
Article in En | MEDLINE | ID: mdl-30011933
ABSTRACT
γ-Glutamylcyclotransferase (GGCT), which is one of the major enzymes involved in glutathione metabolism, is upregulated in a wide range of cancers-glioma, breast, lung, esophageal, gastric, colorectal, urinary bladder, prostate, cervical, ovarian cancers and osteosarcoma-and promotes cancer progression; its depletion leads to the suppression of proliferation, invasion, and migration of cancer cells. It has been demonstrated that the suppression or inhibition of GGCT has an antitumor effect in cancer-bearing xenograft mice. Based on these observations, GGCT is now recognized as a promising therapeutic target in various cancers. This review summarizes recent advances on the mechanisms of the antitumor activity of GGCT inhibition.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alanine / Enzyme Inhibitors / Molecular Targeted Therapy / Gamma-Glutamylcyclotransferase / Neoplasms Limits: Humans Language: En Journal: Int J Mol Sci Year: 2018 Document type: Article Affiliation country: Japón
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alanine / Enzyme Inhibitors / Molecular Targeted Therapy / Gamma-Glutamylcyclotransferase / Neoplasms Limits: Humans Language: En Journal: Int J Mol Sci Year: 2018 Document type: Article Affiliation country: Japón